- Home
- RIGL vs PPT Comparison
RIGL vs PPT Comparison
Compare RIGL & PPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- PPT
- Stock Information
- Founded
- RIGL 1996
- PPT 1988
- Country
- RIGL United States
- PPT United States
- Employees
- RIGL N/A
- PPT N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- PPT Finance Companies
- Sector
- RIGL Health Care
- PPT Finance
- Exchange
- RIGL Nasdaq
- PPT Nasdaq
- Market Cap
- RIGL 335.5M
- PPT 356.5M
- IPO Year
- RIGL 2000
- PPT N/A
- Fundamental
- Price
- RIGL $38.85
- PPT $3.70
- Analyst Decision
- RIGL Buy
- PPT
- Analyst Count
- RIGL 5
- PPT 0
- Target Price
- RIGL $38.20
- PPT N/A
- AVG Volume (30 Days)
- RIGL 995.6K
- PPT 156.1K
- Earning Date
- RIGL 08-05-2025
- PPT 01-01-0001
- Dividend Yield
- RIGL N/A
- PPT 8.84%
- EPS Growth
- RIGL N/A
- PPT N/A
- EPS
- RIGL 5.43
- PPT N/A
- Revenue
- RIGL $267,921,000.00
- PPT N/A
- Revenue This Year
- RIGL $59.93
- PPT N/A
- Revenue Next Year
- RIGL N/A
- PPT N/A
- P/E Ratio
- RIGL $7.15
- PPT N/A
- Revenue Growth
- RIGL 105.62
- PPT N/A
- 52 Week Low
- RIGL $12.66
- PPT $3.25
- 52 Week High
- RIGL $43.72
- PPT $3.72
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- PPT 54.54
- Support Level
- RIGL $39.00
- PPT $3.64
- Resistance Level
- RIGL $42.08
- PPT $3.73
- Average True Range (ATR)
- RIGL 2.32
- PPT 0.03
- MACD
- RIGL -0.37
- PPT 0.00
- Stochastic Oscillator
- RIGL 53.26
- PPT 61.11
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About PPT Putnam Premier Income Trust
Putnam Premier Income Trust is a Massachusetts business trust operating as a non-diversified closed-end management investment company. The fund is currently operating as a diversified fund. Its investment objective is to seek high current income consistent with the preservation of capital by allocating its investments to the U.S. government sector.